Goldman SachsGSBUYJan 20, 2014Stock price when the opinion was issued
As of Jul 21, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
Great company. This and Morgan Stanley (JPM-N) are going to do very well over the next little while. They are not expensive. Have cut their costs way down. A lot of these companies are flush with cash so there is going to be more M&A that is going to go one. Trading at 11X estimated earnings, which is not expensive.